Portiuncula University Hospital
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
At Portiuncula University Hospital researchers are focusing on preventing surgical infections that can follow abdominal operations. The studies aim to test a new anti‑infective agent used alongside standard care to reduce the incidence of incisional infections.
- Evaluation of anti‑infective efficacy of D‑PLEX after surgery
- Comparison with standard of care alone
- Safety monitoring of combined therapy
With five investigators overseeing six trials, the work contributes to safer postoperative outcomes for patients in Galway.
Cardiovascular Diseases
The department is investigating novel drug combinations to lower heart‑related events in people with type 2 diabetes, hypertension, and established cardiovascular disease. The goal is to demonstrate superior protection against cardiovascular death, heart‑failure hospitalization, or urgent visits.
- Combination of vicadrostat and empagliflozin
- Assessment of time to first CV event
- Evaluation of safety in a high‑risk population
This research aligns with the hospital’s commitment to improving heart health for patients across Ireland.
Digestive System Diseases
Clinical investigations at the site are comparing targeted biologic therapies for inflammatory bowel conditions such as moderate to severe Crohn’s disease and ulcerative colitis. The trials seek to identify the most effective and safest treatment options for patients who have not responded to earlier therapies.
- Head‑to‑head comparison of risankizumab versus vedolizumab
- Study of new targeted therapies for Crohn’s disease
- Safety and efficacy monitoring over 48 weeks
By enrolling adult participants, the research aims to expand therapeutic choices for digestive health in the region.
Respiratory Tract Diseases
The hospital’s respiratory program is evaluating biologic agents that target type‑2 inflammation in conditions like eosinophilic asthma and chronic obstructive pulmonary disease. Trials compare the new treatments with existing high‑dose inhaled therapies to improve symptom control.
- Benralizumab add‑on therapy for eosinophilic asthma
- Depemokimab versus placebo in COPD
- Assessment of safety and lung function outcomes
These studies support the goal of delivering personalized respiratory care to patients in Galway and beyond.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Portiuncula University Hospital
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis | Abivax | Phase III | Not Recruiting | Jun 2023 | Jun 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Risankizumab | 2 | Unknown | 2024-11-21 | 2025-07-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.